Last checked at 11 Apr 2024 17:13
FTSE 100 edges lower as financials drag
Lok'nStore surges to all-time high after buyout by Shurgard
*Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Astrazeneca Share News (AZN)
AZN Share
Price
AZN Share
News
AZN Share
Chat
AZN Share
Trades16,417
AZN
Live RNS
AZN Share
Charts
AZN Level 2
Console
AZN Live
Share Price
AZN Broker
Ratings
AZN Directors
Deals
AZN Financial
Diary
AZN
Fundamentals
AZN Short
Positions
AZN
Media
Astrazeneca Information
Share Price Information for Astrazeneca (AZN)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
12,050.00
Bid:
12,038.00
Ask:
12,040.00
Change:
-106.00 (-0.87%)
Spread:
2.00 (0.017%)
Open:
12,092.00
High:
12,178.00
Low:
12,010.00
Prev. Close:
12,156.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Astrazeneca raises guidance after better-than-expected Q2
Thu, 31st Jul 2014 08:42
- Core EPS and revenue outlook raised- H1 revenue up 3%, Q2 revenue up 4%- Q2 PBT of $1.89bnAstrazeneca has lifted its guidance for the year after delivering a 4% increase in second quarter revenue to $6.4bn, ahead of expectations. Half year turnover at the drugs giant climbed 3%, driven by gains across all five of its growth areas, particularly Diabetes, which jumped 128% following the successful integration of the BMS assets and the launch of Farxiga in the US.For the full year, revenue is expected to be in line with the prior year at constant exchange rates (CER), compared to previous guidance of a low-to-mid single digit percentage decline.Although core earnings per share (EPS) were down 1% for the six-month period, they rose 13% to $1.30 in the second quarter, ahead of consensus expectations of $1.06, and as such the group now expects the decrease for the year to be in the low double digits at CER, an improvement on the previous guidance of a percentage decrease in the teens. Core profit before tax came in at $1.89bn, beating consensus estimates for $1.70bn, but down from the $1.94bn reported last year. The FTSE 100-listed group, which on Wednesday announced that it had struck a deal to acquire the respiratory franchise of drugs maker Almirall, posted EPS of 63 cents and 103 cents for the second quarter and first half, respectively. Chief executive officer Pascal Soriot said the group had made "significant progress" during the first half, with momentum visible across its cardiovascular, diabetes and respiratory franchises as well as strong growth in the emerging markets. "This has driven revenue growth for the second consecutive quarter and achieved a 13% increase in core EPS in the quarter. The pace of execution of our strategy and the underlying performance of our teams give us confidence to raise 2014 guidance for the full year." He added that the board's confidence in the company's longer term prospects was underpinned by the current pipeline and the "quality of transformation we are seeing across all core areas of our business". The group's pipeline includes 114 projects, of which 100 are in the clinical phase of development. During the second quarter, 19 projects were moved on to their next phase, including nine new molecular entities (NMEs) and 10 new molecules that have entered first human testing. Four projects were withdrawn. Panmure Gordon analyst Savvas Neophytou said it made no changes to its forecasts for core EPS, which at $4.69 is already ahead of consensus of $4.36, reiterating a 'hold' recommendation and 4,400p target price. Shares had edged 0.07% higher to 4,360.50p by 08:42NR
More News
11 Apr 2024 17:07
Banks weigh down Europe's STOXX 600 after ECB signals rate cuts
Outlook hike sends Ambu shares up
*Read more11 Apr 2024 15:56
London close: Stocks finish lower as ECB stands pat
(Sharecast News) - London's stock markets finished in negative territory on Thursday, as investors reacted to the European Central Bank's latest policy announcement and a producer price index release in the United States.
Read more11 Apr 2024 11:50
LONDON MARKET MIDDAY: Europe takes hit on nerves ahead of ECB decision
(Alliance News) - European equities sunk lower at midday on Thursday, with sentiment hurt by hotter-than-expected inflation from the US crushing hopes of interest rate cuts.
Read more11 Apr 2024 08:56
TOP NEWS: Astra plans 7% dividend hike for 2024 after no rise in 2023
(Alliance News) - AstraZeneca PLC said it intends to raise its annualised dividend for 2024, citing confidence in its business performance and cash generation.
Read more11 Apr 2024 08:54
LONDON MARKET OPEN: European markets mixed ahead of ECB decision
(Alliance News) - European equities lacked direction early Thursday morning, ahead of an interest rate decision from the European Central Bank this afternoon.
Read more11 Apr 2024 07:49
LONDON BRIEFING: Astra promises dividend hike; Darktrace ups guidance
(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye the latest interest rate decision from the European Central Bank, a day after a hotter-than-expected US inflation reading.
Read more11 Apr 2024 07:20
AstraZeneca to hike 2024 dividend by 7%
(Sharecast News) - Biopharma giant AstraZeneca has announced that it will increase its annual dividend by 7%, which the board said demonstrates its confidence in the company's performance and cash generation.
Read more8 Apr 2024 08:36
TOP NEWS: AstraZeneca hails neurological data for Ultomiris, Soliris
(Alliance News) - AstraZeneca PLC on Monday said long-term data in generalised myasthenia gravis will underscore the "vital role" of its Ultomiris and Soliris antibodies in the treatment landscape.
Read more8 Apr 2024 07:43
LONDON BRIEFING: Astra hails neurology data; CVS flags cyberattack
(Alliance News) - London's FTSE 100 is called to open a touch higher on Monday, ahead of an interest rate decision in the eurozone and a US inflation reading later in the week.
Read more8 Apr 2024 07:02
AstraZeneca's Enhurtu cancer gets US green light for adult patients
(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has been approved in the US for adult patients with unresectable or metastatic solid tumours who have received prior systemic treatment and have no satisfactory alternative options.
Read more8 Apr 2024 06:53
TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval
(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Saturday announced that the US Food & Drug Administration has approved their cancer drug conjugate for patients with metastatic HER2-positive solid tumours.
Read more5 Apr 2024 09:42
AstraZeneca makes "breakthrough" in treating small cell lung cancer
(Alliance News) - AstraZeneca PLC on Friday reported positive results relating to its Imfinzi cancer treatment in phase III trials.
Read more5 Apr 2024 07:50
LONDON BRIEFING: Shell to book USD600 million first-quarter write-off
(Alliance News) - London's FTSE 100 is called to open lower on Friday, with hawkish remarks from Federal Reserve policymakers and fears of ratcheting Middle East tensions giving investors little to cheer about ahead of the latest US jobs data.
Read more5 Apr 2024 07:23
AstraZeneca announces positive lung cancer treatment trial results
(Sharecast News) - AstraZeneca announced positive high-level results from a phase three trial demonstrating significant advancements in the treatment of limited-stage small cell lung cancer (LS-SCLC) on Friday.
Read more